Adavosertib

Drug Overview

Adavosertib (also known by its research code AZD1775) is a groundbreaking, experimental cancer medicine. It belongs to a modern class of “smart drugs” known as Targeted Therapy. Unlike traditional chemotherapy that attacks all fast-growing cells, adavosertib is designed to exploit a specific weakness found in the DNA of cancer cells.

Currently, this medicine is being studied in numerous global clinical trials. It is most often used in combination with other treatments to make them more effective.

• Generic Name: Adavosertib (AZD1775)
• US Brand Names: None (Investigational Drug)
• Drug Class: Small molecule inhibitor; WEE1 Kinase Inhibitor.
• Route of Administration: Oral (taken by mouth as a capsule).
• FDA Approval Status: Investigational. It is not yet FDA-approved for general use but is available to patients through regulated clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how adavosertib works, imagine a cell’s life as a car driving down a road. Before the car can cross an intersection (divide into two cells), it must pass a “safety inspection” to ensure its DNA is not damaged. This safety stop is controlled by a protein called WEE1.

Here is the molecular process:

• The G2 Checkpoint: Normal cells use WEE1 to pause the cell cycle at a spot called the G2 checkpoint. This pause gives the cell time to repair any broken DNA before it divides.
• Cancer’s Weakness: Many cancer cells have a broken “backup” safety stop (the G1 checkpoint). Because of this, they rely almost entirely on the WEE1 protein to fix their DNA.
• The “Crash” Strategy: Adavosertib blocks the WEE1 protein. When WEE1 is blocked, the cancer cell cannot stop to fix its broken DNA. It is forced to divide while its DNA is still shattered. This leads to a “mitotic catastrophe”—the cancer cell essentially crashes and dies.
• Chemo-Sensitization: When given with chemotherapy, adavosertib prevents the cancer cell from repairing the damage caused by the chemo, making the treatment significantly more powerful.

FDA Approved Clinical Indications

As an investigational drug, adavosertib does not yet have official FDA-approved indications. However, it is showing great promise in clinical trials for the following:

• Oncological Uses (In Clinical Trials):
  • Ovarian Cancer: Particularly “TP53-mutant” or platinum-resistant types.
  • Uterine Serous Carcinoma: A rare and aggressive form of uterine cancer.
  • Pancreatic Cancer: Used in combination with radiation and chemotherapy.
  • Glioblastoma: Brain tumors that have specific genetic markers.
  • Colorectal Cancer: Often tested in combination with other targeted pills.
• Non-Oncological Uses:
  • None. This drug is specifically designed to target the cell cycle of tumors.

Dosage and Administration Protocols

Dosing for adavosertib is highly specific and often follows a “pulsed” schedule (a few days on, then several days off) to allow healthy cells to rest.

Dose Adjustments

• Renal (Kidney) or Hepatic (Liver) Insufficiency: Patients in trials must have strong organ function. If liver enzymes or kidney filtration levels worsen, the dose is typically lowered by 25% to 50% or paused entirely.
• Combination Therapy: When given with chemotherapy, the dose of adavosertib is usually lower (e.g., 175 mg) to prevent excessive side effects.

Clinical Efficacy and Research Results

Recent data from 2020–2025 has highlighted the drug’s potential in aggressive cancers:

• Uterine Cancer (2021 Data): In a Phase 2 study of patients with uterine serous carcinoma, adavosertib alone showed an Overall Response Rate (ORR) of 29.4%. The median time before the cancer started growing again (PFS) was 6.1 months, which is a significant result for this difficult-to-treat cancer.
• Ovarian Cancer (2023 Data): When combined with chemotherapy (carboplatin), adavosertib improved the time patients lived without their cancer worsening compared to chemotherapy alone.
• Molecular Targeting: Research shows that tumors with a “TP53 mutation” (found in about 50% of all human cancers) are the most likely to respond to this drug, making it a cornerstone of future Targeted Therapy.

Safety Profile and Side Effects

Because adavosertib interferes with cell division, it can affect healthy fast-growing cells, such as those in the blood and the stomach.

Common Side Effects (>10%)

• Diarrhea: One of the most common issues; usually manageable with standard medicine.
• Nausea and Vomiting: Often occurs shortly after taking the capsules.
• Hematologic Toxicity: Lowered counts of white blood cells (neutropenia), red blood cells (anemia), and platelets.
• Fatigue: A general feeling of weakness or exhaustion.

Serious Adverse Events

• Severe Myelosuppression: A dangerous drop in blood cells that can lead to life-threatening infections or internal bleeding.
• Dehydration: Caused by severe diarrhea or vomiting if not treated quickly.
• Pneumonitis: Rare but serious inflammation of the lung tissue.

Management Strategies

• Anti-diarrheals: Medicines like loperamide are often prescribed to be kept on hand.
• Anti-emetics: Patients are often given nausea medication to take 30 minutes before their adavosertib dose.
• Growth Factors: In some cases, injections may be used to boost white blood cell counts.

Connection to Stem Cell and Regenerative Medicine

While adavosertib is primarily a cancer killer, researchers are studying its “epigenetic” effects on cell survival. In the world of Regenerative Medicine, understanding how WEE1 controls the cell cycle helps scientists learn how to make healthy stem cells grow faster or stay in a “quiet” state until they are needed to repair tissue. Additionally, adavosertib is being tested in combination with Immunotherapy (like PD-1 inhibitors) because the DNA damage it causes in tumors may “wake up” the immune system, helping it recognize and destroy cancer stem cells.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Genetic Testing: To check for TP53 mutations or other markers that predict success.
• Complete Blood Count (CBC): To ensure blood levels are safe before starting.
• Pregnancy Test: Adavosertib is hazardous to a developing fetus.

Precautions During Treatment

• Infection Risk: Avoid large crowds or people who are visibly sick.
• Sun Sensitivity: Some patients report increased sensitivity to sunlight.

Do’s and Don’ts

• DO take the medication on an empty stomach (1 hour before or 2 hours after a meal) for better absorption.
• DO drink at least 8 glasses of water a day to prevent dehydration.
• DO tell your doctor about all other medicines, as many drugs (like certain antifungals or heart meds) can cause adavosertib to reach toxic levels.
• DON’T eat grapefruit or drink grapefruit juice, as it significantly increases the drug’s side effects.
• DON’T skip doses or change the “pulsed” schedule without consulting your oncology team.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Adavosertib is an investigational drug and is not currently FDA-approved for standard clinical use. Treatment should only be administered by qualified professionals within an approved clinical trial. Always consult with your oncologist or healthcare provider regarding any diagnosis or treatment plan.